SLC5A1 and diabetes mellitus: 2014; Merovci et al. 2014), must also be evaluated. Despite these potential concerns, the fact that DKO mice had lower fasting and fed blood glucose levels throughout the day relative to SGLT2 KO littermate mice (Powell et al. 2013a) suggests that dual SGLT1/SGLT2 inhibitors merit further evaluation for their potential, in patients with diabetes, to achieve significantly better glycemic control than is currently achieved using selective SGLT2 inhibitors.